The future of transplantation

We are developing an innovative and safe treatment with the potential to change the lives of transplant patients.

Siplizumab is an investigational drug in clinical stage development. There is no guarantee that it will receive regulatory approval and become commercially available for the uses being investigated.

Patient experience

Jennifer is the first HLA-mismatched patient in the world to successfully receive a kidney transplant where transplantation tolerance was actively induced. She has now lived more than 15 years without having to take any anti-rejection immunosuppression. Listen to the short version here of how ITBMed´s therapy helped change her life. Click below for extended version.

Transforming transplantation

The life-long immunosuppression associated with transplantation negatively impacts patients’ health and the transplanted organ itself. With the therapy developed at ITBMed it has been proven that patients can live a life completely without immunosuppression, leading to improved quality of life and reduced health care costs. Listen to Professor David Sachs explain the clinical problems facing the field of transplantation, and how our lead candidate Siplizumab can help improve the lives of transplant patients.

The path of Siplizumab

After 20 years of research at Harvard University and Massachusetts General Hospital we are at the doorstep of transforming transplantation of solid organs. Siplizumab is an anti-CD2 monoclonal antibody specifically targeting an immune pathway leading to a combination of unique effects which makes it ideal in the treatment of transplant patients. Read more about the history of Siplizumab here.

Project pipeline

Siplizumab has great potential as a specific immune modulatory biologic in solid organ transplantation, bone marrow transplantation, and in gene therapy.